Kairos Pharma reports interim Phase 2 progression‑free survival benefit for ENV‑105 plus apalutamide
Kairos Pharma announced that its Phase 2 trial of ENV‑105 combined with apalutamide in metastatic castration‑resistant prostate cancer showed a median progression‑free survival of 17.7 months versus 2 months with apalutamide alone. The interim analysis was statistically significant (P=0.0008). The company has revised the protocol to enroll patients earlier in disease progression and now targets trial completion by the fourth quarter of 2027. CEO Dr. John Yu said the data provide an important clinical signal for the CD105‑targeting antibody.
Why it matters
The company says the interim results support its strategy of targeting drug‑resistance mechanisms, which could improve future market perception of the candidate. Investors may view the data as a catalyst for the stock, which is currently trading around $1.54.
Key facts
- 1Median progression‑free survival was 17.7 months with ENV‑105 plus apalutamide versus 2 months with apalutamide alone. tradingview.com
- 2The difference was statistically significant (P=0.0008). tradingview.com
- 3The Phase 2 trial is now targeted for completion in or before Q4 2027. tradingview.com
- 4The protocol was modified to enroll patients earlier after a PSA rise following upfront androgen‑signalling inhibitor therapy. tradingview.com
- 5KAPA’s stock was down 0.65% at $1.54 at the time of reporting. rttnews.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.